We recently published a list of 10 Stocks Under $10 that Will Triple. In this article, we are going to take a look at where ...

The heavy selling pressure might have exhausted for Arvinas (ARVN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in ...

HC Wainwright restated their buy rating on shares of Arvinas (NASDAQ:ARVN – Free Report) in a research report report published on Monday morning,Benzinga reports. They currently have a $81.00 price ...

Piper Sandler lowered the firm’s price target on Arvinas (ARVN) to $24 from $67 on narrowed vepdegestrant ESR1-mutant mBC approval, while ...

Arvinas, Inc. (NASDAQ:ARVN – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the fifteen brokerages that are currently covering the company, MarketBeat reports. Five ...

Arvinas is continuing its investigation of arv-102 in neurodegenerative diseases associated with lrrk2 and lysosome ...

Arvinas' ARV-102 reduced LRRK2 protein in a Phase 1 trial, showing promising safety and pharmacodynamic outcomes for ...

The Phase I trial saw repeated oral doses of ARV-102 able to more than half the protein suspected to play a factor in ...

Arvinas (ARVN) presented data from the first-in-human clinical trial of ARV-102, the Company’s investigational PROteolysis TArgeting Chimera ...

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at ...

According to TipRanks.com, Risinger is a 5-star analyst with an average return of 8.5% and a 54.1% success rate. Risinger covers the Healthcare sector, focusing on stocks such as Structure ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...